Inhibition of protein synthesis by chromium(VI) differentially affects expression of urokinase and its receptor in human type II pneumocytes

Toxicology and Applied Pharmacology

Volumn 158, Issue 3, 1999, Pages 288-295

  Shumilla, Jennifer A ^b   Barchowsky, Aaron ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Chromium(VI); Extracellular matrix; Fibrinolysis; uPA receptor; Urokinase

Indexed keywords

CHROMIUM 51; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME INACTIVATION; FIBRINOLYSIS; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL TYPE 2; LUNG CARCINOGENESIS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RADIATION EXPOSURE;

EID: 0033180393     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8704     Document Type: Article

References (40)

1. Alcedo J. A., Misra M., Hamilton J. W., Wetterhahn K. E. The genotoxic carcinogen chromium(VI) alters the metal-inducible expression but not the basal expression of the metallothionein gene in vivo. Carcinogenesis. 15:1994;1089-1092.
2. Alcedo J. A., Wetterhahn K. E. Chromium toxicity and carcinogenesis. Int. Rev. Exp. Pathol. 31:1990;85-108.
3. Altus M. S., Nagamine Y. Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. J. Biol. Chem. 266:1991;21190-21196.
4. 1 cells increases calcitonin-induced plasminogen-activator gene transcription and mRNA stability. Biochem. J. 242:1987;387-392.
5. Barchowsky A., Lannon B. M., Elmore L. C., Treadwell M. D. Increased focal adhesion kinase- and urokinase-type plasminogen activator receptor-associated cell signaling in endothelial cells exposed to asbestos. Environ. Health Perspect. 105:1997;1131-1137.
6. Barchowsky A., Roussel R. R., Krieser R. J., Mossman B. T., Treadwell M. D. Expression and activity of urokinase and its receptor in endothelial and pulmonary epithelial cells exposed to asbestos. Toxicol. Appl. Pharmacol. 152:1998;388-396.
7. Bertozzi P., Astedt B., Zenzius L., Lynch K., LeMaire F., Zapol W., Chapman H. A. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. New Engl. J. Med. 322:1990;890-897.
8. Blankenship L. J., Manning F. C. R., Orenstein J. M., Patierno S. R. Apoptosis is the mode of cell death caused by carcinogenic chromium. Toxicol. Appl. Pharmacol. 126:1994;75-83.
9. Borges K. M., Wetterhahn K. E. Chromium cross-links glutathione and cysteine to DNA. Carcinogenesis. 10:1989;2165-2168.
10. Cajot J. F., Bamat J., Bergonzelli G. E., Kruithof E. K. O., Medcalf R. L., Testuz J., Sordat B. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc. Natl. Acad. Sci. USA. 87:1990;6939-6943.
11. Carmeliet P., Schoonjan L., Kieckens L., Ream B., Degen J., Bronson R., DeVos R., van den Oord J. J., Collen D., Milligan R. C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 368:1994;419-424.
12. Chapman H. A., Allen C. L., Stone O. L. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am. Rev. Respir. Dis. 133:1986;437-443.
13. Connett P. H., Wetterhahn K. E. Metabolism of the carcinogen chromate by cellular Constituents. Struct. Bond. 54:1983;93-124.
14. Costa M. Toxicity and carcinogenicity of Cr(VI) in animal models and humans. Crit. Rev. Toxicol. 27:1997;431-442.
15. Dano K., Andreasen P. A., Grondahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44:1985;139-266.
16. Dudek E. J., Wetterhahn K. E. Analysis of steady-state mRNA levels of catalase and heme oxygenase in cultured rat FAO cells treated with chromium(VI), using solution hybridization. New J. Chem. 18:1994;411-417.
17. Franklin T. J. Therapeutic approaches to organ fibrosis. Int. J. Biochem. Cell Biol. 29:1997;79-89.
18. Hamilton J. W., Wetterhahn K. E. Differential effects of chromium(VI) on constitutive and inducible gene expression in chick embryo liver in vivo and correlation with chromium(VI)-induced DNA Damage. Mol. Carcinogenesis. 2:1989;274-286.
19. Iwasaka C., Tanaka K., Abe M., Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plaminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J. Cell. Physiol. 169:1996;522-531.
20. Kotani I., Sato A., Hayakawa H., Urano T., Takada Y., Takada A. Increased procoagulant and antifibrinolytic activities in the lung with idiopathic pulmonary fibrosis. Throm. Res. 77:1995;493-504.
21. Lee K. P., Ulrich C. E., Geil R. G., Trochimowicz H. J. Inhalation toxicity of chromium dioxide dust to rats after two years exposure. Sci. Total Environ. 86:1989;83-108.
22. Li Y., Lieberman M. W. Two genes associated with liver cancer are regulated by different mechanisms in ras T24 transformed liver epithelial cells. Oncogene. 4:1989;795-798.
23. Lund L. R. Expression of urokinase-type plasminogen activator, its receptor and type-1 plasminogen activator inhibitor is differently regulated by inhibitors of protein synthesis in human cancer cell lines. FEBS Lett. 383:1996;139-144.
24. Manning F. C. R., Xu J., Patierno S. R. Transcriptional inhibition by carcinogenic chromate: Relationship to DNA damage. Mol. Carcinogenesis. 6:1992;270-279.
25. Martin B. D., Schoenhard J. A., Sugden K. D. Hypervalent chromium mimics reactive oxygen species as measured by the oxidant-sensitive dyes 2′,7′-dichlorofluorescin and dihydrorhodamine. Chem. Res. Toxicol. 11:1998;1402-1410.
26. Mattagajasingh S. N., Misra H. P. Alterations in the prooxidant and antioxidant status of human leukemic T-lymphocyte MOLT4 cells treated with potassium chromate. Mol. Cell. Biochem. 142:1995;61-70.
27. Miller C. A., Costa M. Immunological detection of DNA-protein complexes induced by chromate. Carcinogenesis. 10:1989;667-672.
28. Mira-Y-Lopez R. Retinoic acid priming potentiates the induction of Urokinase-type plasminogen Activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells. J. Cell. Physiol. 147:1991;46-54.
29. Olman M. A., Mackman N., Gladson C. L., Moser K. M., Loskutoff D. J. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung Injury in the mouse. J. Clin. Invest. 96:1995;1621-1630.
30. Pappot H., Gardsvoll H., Romer J., Pedersen A. N., Grondahl-Hansen J., Pyke C., Brunner N. Plasminogen activator inhibitor type 1 in cancer: Therapeutic and prognostic implications. Biol. Chem. Hoppe-Seyler. 376:1995;259-267.
31. Saksela O., Rifkin D. B. Cell-associated plasminogen activation: Regulation and physiological Functions. Annu. Rev. Cell Biol. 4:1988;93-126.
32. Shainkin-Kestenbaum R., Caruso C., Berlyne G. M. Effect of chromium on oxygen free radical metabolism, inhibition of superoxide dismutase and enhancement of 6-hydroxydopamine oxidation. J. Trace Elem. Electrolytes Health Dis. 5:1991;197-201.
33. Shetty S., Idell S. A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells. Am. J. Physiol. 274:1998;L871-L882.
34. Shetty S., Kumar A., Idell S. Posttranscriptional regulation of urokinase receptor mRNA: Identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol. Cell. Biol. 17:1997;1075-1083.
35. Simon R. H., Gross T. J., Edwards J. A., Sitrin R. G. Fibrin degradation by rat pulmonary alveolar epithelial cells. Am. J. Physiol. 262:1992;L482-L488.
36. Susa N., Ueno S., Furukawa Y., Sugiyama M. Protective effect of vitamin E on chromium (VI)-induced cytotoxicity and lipid peroxidation in primary cultures of rat hepatocytes. Arch. Toxicol. 71:1996;20-24.
37. Tsapakos M. J., Wetterhahn K. E. The interaction of chromium with nucleic acids. Chem.-Biol. Interact. 46:1983;265-277.
38. Wang J. F., Engelsberg B. N., Johnson S. W., Witmer C., Merrick W. C., Rozmiarek H., Billings P. C. DNA binding activity of the mammalian translation elongation complex: Recognition of chromium- and transplatin-damaged DNA. Arch. Toxicol. 71:1997;450-454.
39. Wetterhahn K. E., Hamilton J. W. Molecular basis of hexavalent chromium carcinogenicity: Effect on gene expression. Sci. Total Environ. 86:1989;113-129.
40. Zhitkovich A., Voitkun V., Costa M. Formation of the amino acid-DNA complexes by hexavalent and trivalent chromium in vitro: Importance of trivalent chromium and the phosphate group. Biochemistry. 35:1996;7275-7282.